Erratum
After publication of our article [1], it came to our attention that we had erroneously stated that the IVIG product NewGam was produced by Sutter Health. However, Octapharma is the manufacturer of NewGamTM and Sutter Health is the sponsor of the clinical trial. Therefore the following sentence on page 2 of the original manuscript [1] is incorrect: "The effects of Sutter Health's IVIG NewGamTM are also being examined in individuals with mild cognitive impairment (MCI) [33], thought to be the transitional state between the cognitive changes of normal aging and very early dementia [34]." This sentence should read as follows: “The effects of Octapharma's IVIG NewGamTM are also being examined in individuals with mild cognitive impairment (MCI) [33], thought to be the transitional state between the cognitive changes of normal aging and very early dementia [34].”
Reference
Loeffler DA. Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered? J Neuroinflammation. 2014;11:198.
Author information
Authors and Affiliations
Corresponding author
Additional information
Competing interests
The author declares that he has no competing interests.
The online version of the original article can be found under doi:10.1186/s12974-014-0198-z.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Loeffler, D.A. Erratum: Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?. J Neuroinflammation 12, 68 (2015). https://doi.org/10.1186/s12974-015-0290-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12974-015-0290-z